FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2915691175> ?p ?o ?g. }

• W2915691175 endingPage "451" @default.
• W2915691175 startingPage "441" @default.
• W2915691175 abstract "Suvorexant is an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. As suvorexant is metabolized primarily by Cytochrome P450 3A (CYP3A), and its pharmacokinetics may be affected by CYP3A modulators, the effects of CYP3A inhibitors (ketoconazole or diltiazem) or an inducer (rifampin [rifampicin]) on the pharmacokinetics, safety, and tolerability of suvorexant were investigated. In two Phase I, open-label, fixed-sequence trials (Studies P008 and P038), healthy subjects received a single oral dose of suvorexant followed by co-administration with multiple once-daily doses of strong/moderate CYP3A inhibitors (ketoconazole/diltiazem) or a strong CYP3A inducer (rifampin). Treatments were administered in the morning: suvorexant 4 mg with ketoconazole 400 mg (Study P008; N = 10), suvorexant 20 mg with diltiazem 240 mg (Study P038; N = 20), and suvorexant 40 mg with rifampin 600 mg (Study P038; N = 10). Area under the plasma concentration–time curve from time zero to infinity (AUC0–∞), maximum plasma concentration (Cmax), half-life (t½), and time to Cmax (tmax) were derived from plasma concentrations of suvorexant collected at prespecified time points up to 10 days following CYP3A inhibitor/inducer co-administration. Adverse events (AEs) were recorded. Co-administration with ketoconazole resulted in increased exposure to suvorexant [AUC0–∞: geometric mean ratio (GMR); 90% confidence interval (CI) 2.79 (2.35, 3.31)] while co-administration with diltiazem resulted in a lesser effect [GMR (90% CI): 2.05 (1.82, 2.30)]. Co-administration with rifampin led to a marked decrease (88%) in suvorexant exposure. Consistent with morning administration and known suvorexant pharmacology, somnolence was the most frequently reported AE. These results are consistent with expectations that strong CYP3A inhibitors and inducers exert marked effects on suvorexant pharmacokinetics. In the context of a limited sample size, single suvorexant doses were generally well tolerated in healthy subjects when co-administered with/without a CYP3A inhibitor/inducer." @default.
• W2915691175 created "2019-03-02" @default.
• W2915691175 creator A5001969147 @default.
• W2915691175 creator A5029825407 @default.
• W2915691175 creator A5041269947 @default.
• W2915691175 creator A5061401383 @default.
• W2915691175 creator A5075186864 @default.
• W2915691175 creator A5081640446 @default.
• W2915691175 creator A5087795618 @default.
• W2915691175 creator A5089493156 @default.
• W2915691175 creator A5091864893 @default.
• W2915691175 date "2019-02-27" @default.
• W2915691175 modified "2023-10-10" @default.
• W2915691175 title "Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects" @default.
• W2915691175 cites W1416628922 @default.
• W2915691175 cites W1581771528 @default.
• W2915691175 cites W1966757180 @default.
• W2915691175 cites W1988065740 @default.
• W2915691175 cites W2004576165 @default.
• W2915691175 cites W2012627536 @default.
• W2915691175 cites W2027740042 @default.
• W2915691175 cites W2030021013 @default.
• W2915691175 cites W2049082572 @default.
• W2915691175 cites W2054040800 @default.
• W2915691175 cites W2067516153 @default.
• W2915691175 cites W2075792413 @default.
• W2915691175 cites W2077895426 @default.
• W2915691175 cites W2086139063 @default.
• W2915691175 cites W2105664653 @default.
• W2915691175 cites W2114089215 @default.
• W2915691175 cites W2117685090 @default.
• W2915691175 cites W2132372764 @default.
• W2915691175 cites W2138644435 @default.
• W2915691175 cites W2263589113 @default.
• W2915691175 cites W2492327128 @default.
• W2915691175 cites W2615407691 @default.
• W2915691175 cites W2802758306 @default.
• W2915691175 cites W4225692450 @default.
• W2915691175 doi "https://doi.org/10.1007/s40261-019-00764-x" @default.
• W2915691175 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7018363" @default.
• W2915691175 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30895461" @default.
• W2915691175 hasPublicationYear "2019" @default.
• W2915691175 type Work @default.
• W2915691175 sameAs 2915691175 @default.
• W2915691175 citedByCount "9" @default.
• W2915691175 countsByYear W29156911752020 @default.
• W2915691175 countsByYear W29156911752021 @default.
• W2915691175 countsByYear W29156911752022 @default.
• W2915691175 countsByYear W29156911752023 @default.
• W2915691175 crossrefType "journal-article" @default.
• W2915691175 hasAuthorship W2915691175A5001969147 @default.
• W2915691175 hasAuthorship W2915691175A5029825407 @default.
• W2915691175 hasAuthorship W2915691175A5041269947 @default.
• W2915691175 hasAuthorship W2915691175A5061401383 @default.
• W2915691175 hasAuthorship W2915691175A5075186864 @default.
• W2915691175 hasAuthorship W2915691175A5081640446 @default.
• W2915691175 hasAuthorship W2915691175A5087795618 @default.
• W2915691175 hasAuthorship W2915691175A5089493156 @default.
• W2915691175 hasAuthorship W2915691175A5091864893 @default.
• W2915691175 hasBestOaLocation W29156911751 @default.
• W2915691175 hasConcept C112705442 @default.
• W2915691175 hasConcept C11824378 @default.
• W2915691175 hasConcept C126322002 @default.
• W2915691175 hasConcept C16005928 @default.
• W2915691175 hasConcept C22979827 @default.
• W2915691175 hasConcept C2776741139 @default.
• W2915691175 hasConcept C2777056448 @default.
• W2915691175 hasConcept C2779548794 @default.
• W2915691175 hasConcept C2781064554 @default.
• W2915691175 hasConcept C519063684 @default.
• W2915691175 hasConcept C526171541 @default.
• W2915691175 hasConcept C62231903 @default.
• W2915691175 hasConcept C71924100 @default.
• W2915691175 hasConcept C98274493 @default.
• W2915691175 hasConceptScore W2915691175C112705442 @default.
• W2915691175 hasConceptScore W2915691175C11824378 @default.
• W2915691175 hasConceptScore W2915691175C126322002 @default.
• W2915691175 hasConceptScore W2915691175C16005928 @default.
• W2915691175 hasConceptScore W2915691175C22979827 @default.
• W2915691175 hasConceptScore W2915691175C2776741139 @default.
• W2915691175 hasConceptScore W2915691175C2777056448 @default.
• W2915691175 hasConceptScore W2915691175C2779548794 @default.
• W2915691175 hasConceptScore W2915691175C2781064554 @default.
• W2915691175 hasConceptScore W2915691175C519063684 @default.
• W2915691175 hasConceptScore W2915691175C526171541 @default.
• W2915691175 hasConceptScore W2915691175C62231903 @default.
• W2915691175 hasConceptScore W2915691175C71924100 @default.
• W2915691175 hasConceptScore W2915691175C98274493 @default.
• W2915691175 hasFunder F4320307776 @default.
• W2915691175 hasFunder F4320332161 @default.
• W2915691175 hasIssue "5" @default.
• W2915691175 hasLocation W29156911751 @default.
• W2915691175 hasLocation W29156911752 @default.
• W2915691175 hasLocation W29156911753 @default.
• W2915691175 hasOpenAccess W2915691175 @default.
• W2915691175 hasPrimaryLocation W29156911751 @default.
• W2915691175 hasRelatedWork W1988423359 @default.
• W2915691175 hasRelatedWork W2016605751 @default.

• next